For the quarter ending 2025-09-30, NTLA had $37,217K increase in cash & cash equivalents over the period. -$76,928K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Collaboration revenue | 44,654 | - |
| Research and development | 300,209 | - |
| General and administrative | 86,725 | - |
| Interest income | 22,719 | - |
| Other segment information | -2,653 | - |
| Net loss | -101,324 | -215,584 |
| Depreciation and amortization | 2,415 | 4,972 |
| Gain on disposal of property and equipment | 0 | - |
| Accelerated amortization of right-of-use asset | 2,521 | - |
| Stock-based compensation | 19,604 | 43,876 |
| Accretion of investment discounts | 1,085 | 3,947 |
| Recognition of equity method investment intra-entity profit on sales | 0 | 0 |
| Change in fair value of investments, net | 3,439 | -786 |
| Accounts receivable | -303 | 2,836 |
| Prepaid expenses and other current assets | 23,035 | -5,373 |
| Operating lease right-of-use assets | -8,641 | -16,151 |
| Other assets | -25,288 | 24,415 |
| Accounts payable | 3,459 | -4,431 |
| Accrued expenses | -715 | -13,583 |
| Deferred revenue | -4,907 | -9,224 |
| Operating lease liabilities | -4,625 | -45,690 |
| Net cash used in operating activities | -76,899 | -248,552 |
| Purchases of property and equipment | 29 | 974 |
| Purchases of marketable securities | 116,651 | 138,809 |
| Sales and maturities of marketable securities | 115,939 | 341,021 |
| Net cash provided by (used in) investing activities | -741 | 201,238 |
| Net proceeds from issuance of common stock through at-the-market offerings-At The Market Offerings | 114,760 | 13,415 |
| Proceeds from options exercised | 97 | 0 |
| Issuance of shares through employee stock purchase plan | 0 | 1,237 |
| Net cash provided by financing activities | 114,857 | 14,652 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 37,217 | -32,662 |
| Cash and cash equivalents at beginning of period | 202,787 | - |
| Cash and cash equivalents at end of period | 207,342 | - |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)